Abstract 1528P
Background
Despite therapeutic developments for patients with advanced HER2+ solid tumors, significant unmet medical needs still exist. The T-cell antigen coupler (TAC) technology is an approach to modifying T-cells ex vivo, which allows recognition and cytotoxicity of tumor cells by co-opting the natural T-cell receptor. TAC T-cells demonstrate a safer profile than chimeric antigen receptor T cells. TAC01-HER2 is an autologous T-cell product comprising T-cells expressing HER2 TAC.
Methods
The ongoing clinical trial (NCT04727151) is evaluating the safety and preliminary anti-tumor activity of TAC01-HER2 treatment of HER2+ solid tumors. Subjects undergo leukapheresis followed by lymphodepletion chemotherapy (LDC) prior to TAC01-HER2 infusion. In phase I dose escalation, TAC01-HER2 is administered at increasing doses (Cohorts 1-4) in adult subjects after ≥2 lines of therapy. Dose limiting toxicities (DLT) are assessed up to 28 days from TAC01-HER2 infusion. In phase II, dose expansion groups will further evaluate the safety, efficacy, and pharmacokinetics of the optimal TAC01-HER2 dose in gastric/GEJ tumors.
Results
As of 23 April 2023, 19 patients with solid tumors have been treated in Cohorts 1-4. Three were HER2 1+ or 2+/FISH-. One DLT event of grade (G) 3 pneumonitis has been reported in 1 subject in Cohort 4. No neurotoxicity has been reported. Most subjects treated at Cohorts 3-4 experienced CRS which resolved with supportive therapy. Thirteen subjects have reported a total of 26 serious adverse events, with 1 G3 pneumonitis, 1 G1, 3 G2 and 1 G3 CRS related to TAC01-HER2. A 67% disease control rate (DCR) was observed in Cohorts 2-4 at 4 weeks restaging after TAC01-HER2 infusion. For gastric/GEJ subjects of the same Cohorts, DCR was 83%. Two patients had an unconfirmed partial response (uPR). At Cohort 4, a uPR was observed in a subject with GEJ (HER2 2+, FISH+) with 100% reduction of target lesion. This patient had progressed on 4 prior lines of therapy including trastzumab and trastuzumab deruxtecan.
Conclusions
Treatment with TAC01-HER2 showed manageable safety and promising clinical activity in a heavily pre-treated cancer population. Dose escalation is complete.
Clinical trial identification
NCT04727151.
Editorial acknowledgement
Legal entity responsible for the study
Triumvira Immunologics.
Funding
Triumvira Immunologics.
Disclosure
D. Olson: Financial Interests, Personal, Advisory Board: Novartis, Alphasights, GLG Consulting, MJH Life Sciences; Financial Interests, Institutional, Local PI: Takeda, Astellas, Adaptimmune, Instil Bio, Inhibrix; Non-Financial Interests, Principal Investigator: CTRL Therapeutics. E.E. Dumbrava: Financial Interests, Institutional, Other, Research/grant funding: Bayer HealthCare Pharmaceuticals, Immunocore Ltd., Amgen, Aileron Therapeutics, Compugen Ltd, Gilead, BOLT Therapeutics, Aprea Therapeutics, Bellicum, PMV Pharma, Triumvira, Seagen Inc, Mereo BioPharma 5 Inc, Sanofi, Rain Oncology, Astex Therapeutics, Sotio, Mersana Therapeutics, Poseida, Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: PMV Pharma; Financial Interests, Personal, Advisory Board: Bolt Therapeutics, Mersana Therapeutics, Orum Therapeutics, Summit Therapeutics. M. George: Financial Interests, Personal, Advisory Board: Seattle Genetics, OBI Pharma; Financial Interests, Institutional, Research Grant: Incyte, Oncolytics. S. Saibil: Financial Interests, Personal, Advisory Board: Janssen, Novartis, Sanofi Genzyme. A. Giordano: Financial Interests, Personal, Advisory Board: Pfizer. E. Lichtenstein: Financial Interests, Institutional, Full or part-time Employment: Rutgers Cancer Institute of NJ. M. Apostolopoulou; D. Kirkwood; S. Dang: Financial Interests, Personal, Full or part-time Employment: Triumvira. K. Moss: Financial Interests, Institutional, Full or part-time Employment: Triumvira Immunologics, Inc.; Financial Interests, Personal, Stocks/Shares: Triumvira Immunologics, Inc. D. Adib: Financial Interests, Institutional, Officer: Triumvira; Financial Interests, Institutional, Stocks/Shares: Triumvira; Financial Interests, Institutional, Trial Chair: Triumvira. All other authors have declared no conflicts of interest.
Resources from the same session
1535P - Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Presenter: Magdalena Scheck
Session: Poster session 21
1536P - HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
Presenter: Joshua Tobias
Session: Poster session 21
1537P - A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
Presenter: Daisuke Takahari
Session: Poster session 21
1540P - Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study
Presenter: Yi Zhang
Session: Poster session 21
1541P - Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
Presenter: Yinjun Dong
Session: Poster session 21
1542P - Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
Presenter: Mingfang Xu
Session: Poster session 21